BCR-ABL fusion gene
(Philadelphia translocation/ t9 / 22)
Material: | 3 ml EDTA-blood 2 – 3 ml EDTA bone marrow |
Indication | Philadelphia translocation is seen in 95 % of all patients with chronic myelogenous leukemia (CML), in approximately 2 % of patients with acute myelogenous leukemia (AML) and in approximately 25 % of adults and 5 % of children with acute lymphatic leukemia (ALL). |
Please note | The Philadelphia chromosome is formed by translocation of the abl-proto oncogene of chromosome 9 into the bcr-gene of chromosome 22, with the development of a bcr/abl fusion gene, coding a protein with tyrosine kinase activity. This protein has a proliferation inducing effect. Within the bcr-gene, breakpoints can occur in two regions: the so-called major (M-bcr) breakpoint, and the minor (m-bcr) breakpoint. In CML-patients near enough all breakpoint are of the M-bcr type, whilst ALL-patients show the M-bcr type in 50 % and m-bcr type in 50 % of the cases. |
External services | ja MVZ Dr. Eberhard & Partner Dortmund |
More Results for the letter B
- Blood group serology (BG)
- Blood in stool, immunological (IFOB)
- iFOBT
- Bordetella pertussis/parapertussis (PERT)
- Whooping cough
- Borrelia vincenti (BORR01)
- Spirochaeta vincenti
- Borreliosis (BOR)
- Borrelia burgdorferi and other species
- Botulism (CLOS)
- Clostridium botulinum
- BRCA1 and BRCA2 mutation analysis (BRCA1)
- Brillant cresyl blue staining (BRIL)
- Brivaracetam (BRIVA)
- Bromazepam (BROMA)
- Bromine in serum (BRO)
- as Bromide
- Bronchial lavage / Bronchoalveolar lavage (BAL)
- Brucellosis (BRUC)
- Buprenorphine (BUPR)